The classification of diabetes by clinical and C-peptide criteria: A prospective population-based study

Diabetes Care

Volumn 20, Issue 2, 1997, Pages 198-201

  Service, F John ^a,b   Rizza, Robert A ^a   Zimmerman, Bruce R ^a   Dyck, Peter J ^a   O'Brien, Peter C ^a   Melton III, L Joseph ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; HORMONE RESPONSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0031035178     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.2.198     Document Type: Article

References (25)

1. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1052, 1979
2. Heding LG: Specific and direct radioimmunoassay for human proinsulin in serum. Diabetologia 13:467-477, 1977
3. Faber OK, Binder C: C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus. Diabetes 26:605-610, 1977
4. Heding LG: Insulin C-peptide and proinsulin in nondiabetics and insulin-treated diabetics: characterization of the proinsulin in insulin-treated diabetics. Diabetes 27 (Suppl. 1): 178-183, 1978
5. Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbol I: Prevalence of residual β-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 27 (Suppl. 1):262-264, 1978
6. Mirel RD, Ginsberg-Fellner F, Horwitz DL, Rayfield EJ: C-peptide reserve in insulin dependent diabetes: comparative response to glucose, glucagon and tolbutamide. Diabetologia 19:183-188, 1980
7. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I, Binder C: Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 210:153-156, 1981
8. Welborn TA, Garcia-Webb P, Bonser AM: Basal C-peptide in the discrimination of type I from type II diabetes. Diabetes Care 4:616-619, 1981
9. Garcia-Webb P, Bonser A, Welborn TA: Correlation between fasting serum C-peptide and beta-cell insulin secretory capacity in diabetes mellitus (Letter). Diabetologia 22: 296, 1982
10. Werther GA, Turner RC, Jenkins PA, Baum JD: Twenty-four hour profiles of plasma C-peptide type I (insulin-dependent) diabetic children. Diabetologia 22:245-249, 1982
11. Goldstein DE, Parker KM, England JD, England JE, Wiedmeyer H-M, Rawlings SS, Hess R, Little RR, Simonds JF, Breyfogle RP: Clinical application of glycosylated hemoglobin measurements. Diabetes 31 (Suppl. 3):70-78, 1982
12. Dauzat J, Moinade S, Gaillard G, Glanddier Y, Gachon AM: La réserve insulinique du diabétique insulinodépendant. rôle du peptide C dans l'équilibre du diabète. Presse Med 12:1983-1987, 1983
13. Welborn TA, Garcia-Webb P, Bonser A, McCann V, Constable I: Clinical criteria that reflect C-peptide status in idiopathic diabetes. Diabetes Care 6:315-316, 1983
14. Laakso M, Sarlund H, Pyorala K: Prevalence of insulin deficiency among initially non-insulin-depedent middle-aged diabetic individuals. Diabetes Care 9:228-231, 1986
15. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P: Plasma and urinary C-peptide in the classification of adult diabetics. Scand J Clin Lab Invest 46:655-663, 1986
16. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM: Residual lo-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care 10:33-38, 1987
17. Damsgaard EM, Faber OK, Frøland A, Green A, Hauge M, Holm NV, Iversen S: Prevalence of fasting hyperglycemia and known non-insulin-dependent diabetes mellitus classified by plasma C-peptide: Fredericia survey of subjects 60-74 years old. Diabetes Care 10:26-32, 1987
18. Gjessing HJ, Matzen LE, Faber OK, Frøland A: Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32:305-311, 1989
19. Prior MJ, Prout T, Miller D, Ewart R, Kumar D: C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Ann Epidemiol 3:9-17, 1993
20. Laakso M, Sarlund H, Pyorala K: Clinical characteristics in the discrimination between patients with low or high C-peptide levels among middle-aged insulin-treated diabetics. Diabetes Res 4:95-99, 1987
21. Nielsen NV, Tronier B: C-peptide in diabetes mellitus treated with insulin: a 3-year epidemiological study on the island of Falster, Denmark. Diabetes Res 3:475-478, 1986
22. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ, O'Brien PC, Litchy WJ, Windebank AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR: The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 41:799-807, 1991
23. Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548, 1975
24. The DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes 35:530-545, 1986
25. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, Nuttall F, Sawin C, VA Cooperative Study Group: Glycemic control and complications in type II diabetes: design of a feasibility trial. Diabetes Care 15:1560-1571, 1992